Research Article
Soluble CD14 as a Diagnostic and Prognostic Biomarker in Hematological Patients with Febrile Neutropenia
Table 1
Characteristics of the study population ().
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AML: acute myeloid leukemia; ASCT: autologous stem cell transplant; MM: multiple myeloma; NHL: non-Hodgkin lymphoma; HL: Hodgkin lymphoma; BEAC: carmustine, etoposide, cytarabine, and cyclophosphamide; BEAM: carmustine, etoposide, cytarabine, and melphalan; HD-MEL: high-dose melphalan; Mito-HDAraC: mitoxantrone and high-dose cytarabine; HDAraC-Ida: high-dose cytarabine and idarubicin; IAT: idarubicin, cytarabine, and thioguanine; MEA: mitoxantrone, etoposide, and cytarabine; IdAraC-Ida: intermediate-dose cytarabine and idarubicin. 1Febrile neutropenia with a positive blood culture finding and/or development of severe sepsis or septic shock during the period from the onset of febrile neutropenia until the recovery of neutropenia. 2Severe sepsis was defined as subset of sepsis with sepsis-induced organ dysfunction. 3Septic shock was defined as subset of sepsis with hypoperfusion (systolic arterial pressure < 90 mmHg, a mean arterial pressure < 60 mmHg, or a reduction in systolic blood pressure of >40 mmHg from baseline) despite an adequate volume resuscitation in the absence of other causes of hypotension. |